Adding an intermediate-dose stereotactic ablative radiotherapy (SABR) boost of TKGy to hypofractionated concurrent chemoradiation appears safe and improves outcomes in patients with unresectable, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results